Pharming (PHAR) EBT (2020 - 2026)

Pharming (PHAR) has 7 years of EBT data on file, last reported at $26.1 million in Q2 2026.

• Quarterly EBT rose 687200951.25% year-over-year to $26.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.5 million (up 262.37% YoY) and the FY2025 annual result came in at $12.8 million, up 251.28% from the prior year.
• EBT grew to $26.1 million in Q2 2026, from -$14.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $33.1 million in Q4 2022 to a low of -$16.3 million in Q1 2024.
• A 5-year average of $1.4 million and a median of $4.3 in 2025 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT sank 587.96% — and 2026, when it jumped 687200951.25%.
• Tracing PHAR's EBT over 5 years: stood at $33.1 million in 2022, then sank by 136.29% to -$12.0 million in 2023, then grew by 29.3% to -$8.5 million in 2024, then jumped by 100.0% to $4.8 in 2025, then soared by 544749900.0% to $26.1 million in 2026.
• The last three EBT figures came in at $26.1 million (Q2 2026), -$14.7 million (Q1 2026), and $4.8 (Q4 2025), per Business Quant data.